Valneva SE ADR (VALN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $6.60 (+0.46%), Market cap $0.55B, 52-week low–high $5.17 ~ $12.20.
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetr
Financial statements, price targets, institutional (13F) holdings and related news for Valneva SE ADR are updated in real time on BlackAll Trade.
Valneva SE ADR trades at $6.60 (+0.46%). Real-time quotes and charts are available on BlackAll Trade.
Valneva SE ADR has a market cap of about $0.55B.
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-d